Company intelligence / Profile preview

Salmedix

San Diego, California, United Stateshig.com ↗

Ownership: Private
Development stage: Commercial

Overview

Salmedix developed oncology drugs for hematologic cancers. Its lead asset SDX‑105 was in Phase 2/3 for non-Hodgkin’s lymphoma when acquired by Cephalon in 2005. SDX‑105 later became Treanda® under Cephalon and achieved blockbuster status (> $1 billion sales). Other programs included L-Alanosine and (R)-Etodolac targeting various cancer pathways.

Therapeutic areas: OncologyHematology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

bendamustine

Commercial

Indications: Non-Hodgkin's lymphoma

Beyond the preview

Go deeper on Salmedix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Salmedix.

Explore the full profile